| __timestamp | Ligand Pharmaceuticals Incorporated | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 22570000 | 504755000 |
| Thursday, January 1, 2015 | 24378000 | 838526000 |
| Friday, January 1, 2016 | 26621000 | 1177697000 |
| Sunday, January 1, 2017 | 28653000 | 1320433000 |
| Monday, January 1, 2018 | 37734000 | 1556200000 |
| Tuesday, January 1, 2019 | 41884000 | 1834800000 |
| Wednesday, January 1, 2020 | 64435000 | 1346000000 |
| Friday, January 1, 2021 | 57483000 | 1824900000 |
| Saturday, January 1, 2022 | 70062000 | 2115900000 |
| Sunday, January 1, 2023 | 52790000 | 2631300000 |
| Monday, January 1, 2024 | 2954400000 |
Unveiling the hidden dimensions of data
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Regeneron Pharmaceuticals, Inc. and Ligand Pharmaceuticals Incorporated have showcased contrasting strategies in this domain. From 2014 to 2023, Regeneron consistently reported higher SG&A expenses, peaking at approximately $2.63 billion in 2023, a staggering 1,065% increase from Ligand's $52.79 million in the same year. Despite Regeneron's larger scale, Ligand's ability to maintain lower SG&A costs highlights its efficient cost management. Interestingly, Ligand's expenses grew by 133% over the decade, while Regeneron's surged by 421%. This data underscores the diverse approaches these companies take in balancing growth and operational efficiency. As the pharmaceutical landscape evolves, these insights offer a glimpse into the strategic priorities of industry leaders.
Eli Lilly and Company vs Regeneron Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Mesoblast Limited Trends and Insights
Regeneron Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated: Strategic Focus on R&D Spending
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Ligand Pharmaceuticals Incorporated
Selling, General, and Administrative Costs: Exelixis, Inc. vs Ligand Pharmaceuticals Incorporated
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and Ligand Pharmaceuticals Incorporated
Comparing SG&A Expenses: MorphoSys AG vs Ligand Pharmaceuticals Incorporated Trends and Insights
Comparing SG&A Expenses: Bausch Health Companies Inc. vs Ligand Pharmaceuticals Incorporated Trends and Insights
Cost Management Insights: SG&A Expenses for Ligand Pharmaceuticals Incorporated and Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Ligand Pharmaceuticals Incorporated and Agios Pharmaceuticals, Inc.
Ligand Pharmaceuticals Incorporated or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?